PARP Inhibitors for Metastatic Urothelial Carcinoma: A Systematic Review of Efficacy and Safety [0.03%]
转移性尿路上皮癌PARP抑制剂药物治疗的疗效和安全性系统评价及 meta 分析
Simon J Crabb,Taha Khalid,Lois Woods et al.
Simon J Crabb et al.
Background: Poly (ADP-ribose) polymerase (PARP) inhibitors have activity in various cancers. Metastatic urothelial carcinoma (MUC) is platinum sensitive and a subset harbour DNA repair gene alterations. ...
François Radvanyi,Francisco X Real,David McConkey
François Radvanyi
In an accompanying paper, Mattias Höglund discusses on what is a bladder cancer molecular subtype. He emphasizes the need to consider the aim of tumor classification, which is obviously critical to the approach. He also focuses on consider...
Molecular Basis of Tumorigenesis of Bladder Cancer and Emerging Concepts in Developing Therapeutic Targets [0.03%]
膀胱癌肿瘤发生的分子基础及治疗靶点研究新理念
Rana M Abdeltwab,Elaria Yacoub,Ahmed H Rashad et al.
Rana M Abdeltwab et al.
Background: Advanced urothelial carcinoma (UC) is an aggressive disease whose mutagenic processes are yet to be elucidated. Targeted therapies are urgently needed, but the road from bench to bedside is slowly progressing....
Edward M Messing
Edward M Messing
Piyush K Agarwal,Cora N Sternberg
Piyush K Agarwal
Challenging Cases in Urothelial Cancer: Case 30: Rare Complication of BCG [0.03%]
膀胱癌疑难病例：第30例：卡介苗罕见并发症患者
Mark S Soloway
Mark S Soloway
Commentary on Novitas LCD [0.03%]
诺华视准LCD评论
Yair Lotan,Daniel A Barocas,Sam S Chang et al.
Yair Lotan et al.
No Association Between BCG Instillations and COVID-19 Incidence in a Dutch Non-Muscle Invasive Bladder Cancer Cohort [0.03%]
BCG灌注与荷兰非肌层浸润性膀胱癌队列中的COVID-19发病率无关联
Moniek van Zutphen,Lambertus A L M Kiemeney,Ursula T H Oldenhof et al.
Moniek van Zutphen et al.
Mattias Höglund
Mattias Höglund
Background: Several molecular classification systems for bladder cancer have been proposed, but due to differences on how to define molecular subtypes, controversies and misunderstandings have arisen. ...
Comparative Analysis of Very Reduced vs Full Dose BCG Treatment for High-Risk Non-Muscle Invasive Bladder Cancer: A Contemporary Experience from Chile [0.03%]
低剂量BCG与全剂量BCG治疗高危非肌层浸润性膀胱癌的比较分析：来自智利的当代经验
Valentina Grajales,Roberto Contieri,Wei Shen Tan et al.
Valentina Grajales et al.
Background: Adjuvant bacillus Calmette-Guérin (BCG) is recommended for high-risk (HR) non-muscle invasive bladder cancer (NMIBC), but BCG shortages have led to exploration of reduced-dose regimens and shortened maintenan...